pharmaphorum
JUNE 20, 2022
Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the company’s Orphan Drug Report 2022, which highlights activities within the orphan drug market and forecasts what the future of the industry holds based on data. Revising legislation.
European Pharmaceutical Review
SEPTEMBER 12, 2024
In 2022, Xenpozyme ® (olipudase alfa) became the first and only approved ASMD therapy. Since the first orphan drug legislation was passed over 40 years ago, the landscape has changed rapidly, and patients are benefiting more and more from breakthrough innovations emerging through this scientific revolution.
Expert insights. Personalized for you.
52 
Let's personalize your content